Results 31 to 40 of about 4,376,584 (354)
Interstitial Lung Disease in the Elderly [PDF]
Despite the relationship between idiopathic pulmonary fibrosis (IPF) and advancing age, little is known about the epidemiology of interstitial lung disease (ILD) in the elderly. We describe the diagnoses, clinical characteristics, and outcomes of patients who were elderly at the time of ILD diagnosis.Among subjects from a prospective cohort study of ...
Patterson, Karen C +11 more
openaire +2 more sources
Visual Abstract Interstitial lung diseases (ILDs) comprise over 200 parenchymal lung disorders. Among them, fibrosing ILDs, especially idiopathic pulmonary fibrosis, are associated with a poor prognosis, whereas some other ILDs, such as sarcoidosis, have
M. Röhrich +15 more
semanticscholar +1 more source
Background Silicosis is a progressive pneumoconiosis characterized by interstitial fibrosis following exposure to silica dust. The role of metabolic dysregulation in the pathogenesis of silicosis has not been investigated in detail.
Changjiang Xue +4 more
doaj +1 more source
The prevalence and burden of interstitial lung diseases in the USA
Interstitial lung diseases (ILDs) are a heterogeneous group of diseases (i.e. idiopathic interstitial pneumonias, autoimmune ILDs, environmental exposure-related ILDs, sarcoidosis) but share several common clinical and pathophysiological features [1, 2].
N. Jeganathan, Matheni Sathananthan
semanticscholar +1 more source
Cluster features in fibrosing interstitial lung disease and associations with prognosis
Background Clustering is helpful in identifying subtypes in complex fibrosing interstitial lung disease (F-ILD) and associating them with prognosis at an early stage of the disease to improve treatment management.
Yuanying Wang +5 more
doaj +1 more source
Role of the Microbiome in Interstitial Lung Diseases
There are trillions of microorganisms in the human body, consisting of bacteria, viruses, fungi, and archaea; these collectively make up the microbiome. Recent studies suggest that the microbiome may serve as a biomarker for disease, a therapeutic target,
O. Chioma +3 more
semanticscholar +1 more source
Background Pulmonary fibrosis (PF) is caused by a heterogeneous group of diseases, with a high inter-individual variability in disease trajectory. Identifying disease progression in patients with PF has impact on clinical management decisions.
Gizal Nakshbandi +9 more
doaj +1 more source
Elevated Serum Amyloid A (SAA) levels have been found in several inflammatory diseases, including sarcoidosis. SAA is suggested to be involved in sarcoidosis pathogenesis by involvement in granuloma formation and maintenance.
Els Beijer +5 more
doaj +1 more source
Interstitial lung disease [PDF]
This article reviews the most important articles published in interstitial lung disease, as reviewed during the Clinical Year in Review session at the 2012 annual European Respiratory Society Congress in Vienna, Austria.Since the recent international guidelines for the management of idiopathic pulmonary fibrosis (IPF), important new evidence is ...
openaire +4 more sources
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
BACKGROUND Preclinical data have suggested that nintedanib, an intracellular inhibitor of tyrosine kinases, inhibits processes involved in the progression of lung fibrosis.
K. Flaherty +17 more
semanticscholar +1 more source

